Matão Controlling Hypertension (MatCH Study): Rationale and Design
Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Background Hypertension is the main risk factor for most cardiovascular diseases. Blood
pressure (BP) control has been shown to reduce the incidence of stroke, myocardial
infarction, renal diseases and heart failure. Although BP lowering is effective, few
population programs can achieve BP control. A coordinated and organized system from the
Brazilian Ministry of Healthy involving Family Health Strategy (FHS), a program for the
prevention of chronic disease, and the Popular Pharmacy Program (PPP), which subsidizes
medications for the population, could allow an earlier identification and better BP control.
Matão Controlling Hypertension (MatCH) is a community-based population project that aims to
apply an organized, integrated and coordinated program in the city of Matão, Brazil,
involving FSH and PPP in order to actively search, treat and follow-up hypertensive subjects.
Method This is a population community-based, prospective, interventional, follow-up study
where all subjects aged ≥ 40 years assisted by the FHS program in Matão will have BP assessed
monthly by trained Community Health Agents (CHA) during a domiciliary visit. Identified
hypertensive subjects will be referred to FHS physicians for nonpharmacological and
pharmacological treatment. Most of the hypertensive drugs used will be available thought the
PPP. Prevalence of hypertension, awareness, demographics and risk factors will be correlated
with BP control. The population study is expected to involve approximately 15,000 subjects.
The study period will be four years.
Discussion Considering that hypertension is asymptomatic in most cases, to reduce the
population burden of BP-related deaths and diseases it is essential to detect and treat early
all hypertensive patients. If BP control be achieved on a large scale, this program can be
applied to other populations from developing countries.
Phase:
Early Phase 1
Details
Lead Sponsor:
Centro Neurológico de Pesquisa e Reabiitação, Brazil
Treatments:
Atenolol Captopril Captopril, hydrochlorothiazide drug combination Clonidine Hydrochlorothiazide Losartan